Dr. A. Mark Fendrick explains the concept of Value-Based Insurance Design (VBID) and how it works.
Interviews
Advertisement
Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses challenges faced jointly by the US and EU biosimilars markets.
Advertisement
Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, discusses how confirming "sufficient likeness" in biosimilar development can and should replace the current "totality of the evidence” approach to biosimilar development.
Advertisement
Advertisement
Trending on AJMC
1
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
2
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
3
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
4
Social Factors Shape Diabetes, Dementia Risk Across Populations
5